BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

Rocket Pharmaceuticals will cut 80 jobs and streamline operations, focusing on gene therapies to drive long-term growth.

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

In this exclusive Drug Digest video, Deepak Bahl from Roquette and Jagruti Patel from Lonza look at strategies for ...